The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer.
Xue-Ning Yang
No relevant relationships to disclose
Gang Cheng
No relevant relationships to disclose
Xiao-song Ben
No relevant relationships to disclose
Hong-He Luo
No relevant relationships to disclose
Chang-li Wang
No relevant relationships to disclose
Wenzhao Zhong
No relevant relationships to disclose
Di Ge
No relevant relationships to disclose
Gui-bin Qiao
No relevant relationships to disclose
Zheng Wang
No relevant relationships to disclose
Yang Shentu
No relevant relationships to disclose
Jie Yang
No relevant relationships to disclose
Hong hong Yan
No relevant relationships to disclose
Yi Long Wu
No relevant relationships to disclose